Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease.

Frontiers in Neurology
Naghmeh GhazalehJeffrey Long

Abstract

Huntington's disease (HD) is characterised by a triad of cognitive, behavioural, and motor symptoms which lead to functional decline and loss of independence. With potential disease-modifying therapies in development, there is interest in accurately measuring HD progression and characterising prognostic variables to improve efficiency of clinical trials. Using the large, prospective Enroll-HD cohort, we investigated the relative contribution and ranking of potential prognostic variables in patients with manifest HD. A random forest regression model was trained to predict change of clinical outcomes based on the variables, which were ranked based on their contribution to the prediction. The highest-ranked variables included novel predictors of progression-being accompanied at clinical visit, cognitive impairment, age at diagnosis and tetrabenazine or antipsychotics use-in addition to established predictors, cytosine adenine guanine (CAG) repeat length and CAG-age product. The novel prognostic variables improved the ability of the model to predict clinical outcomes and may be candidates for statistical control in HD clinical studies.

References

Jan 27, 2007·BMC Bioinformatics·Carolin StroblTorsten Hothorn
Dec 22, 2010·Orphanet Journal of Rare Diseases·Raymund A C Roos
Aug 24, 2011·Current Neurology and Neuroscience Reports·Jane S Paulsen
Mar 13, 2014·Nature Reviews. Neurology·Christopher A RossSarah J Tabrizi
May 6, 2014·Frontiers in Aging Neuroscience·Jane S PaulsenUNKNOWN PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Aug 29, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Ralf ReilmannChristopher A Ross
Dec 3, 2014·Lancet Neurology·Jane S PaulsenUNKNOWN PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Feb 6, 2016·American Journal of Human Genetics·Jae Whan KeumJong-Min Lee
Jan 1, 2015·Nature Reviews. Disease Primers·Gillian P BatesSarah J Tabrizi
Sep 30, 2016·The New England Journal of Medicine·Ziad Obermeyer, Ezekiel J Emanuel
Aug 6, 2017·Annals of Neurology·Jorien M M van der BurgN Ahmad Aziz
Aug 25, 2017·Journal of Insurance Medicine·Steven J Rigatti
Sep 15, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Chris FrostUNKNOWN TRACK-HD Investigators
Sep 19, 2017·Lancet Neurology·Edward J Wild, Sarah J Tabrizi
Nov 17, 2017·Neurology·Scott A SchobelUNKNOWN TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators
Sep 14, 2018·Science Translational Medicine·Lauren M ByrneEdward J Wild
Aug 14, 2019·JAMA Neurology·Douglas R LangbehnUNKNOWN TRACK-HD and Track-On HD Groups
Jan 1, 2020·BMC Medical Research Methodology·Shannon WongvibulsinScott L Zeger
Jan 8, 2020·AIMS Public Health·Maria C MarianiMd Al Masum Bhuiyan
Apr 28, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Jordan L SchultzPeg C Nopoulos
Dec 18, 2020·Science Translational Medicine·Filipe B RodriguesEdward J Wild

❮ Previous
Next ❯

Software Mentioned

lme4
Party
lmer
Cforest
HD
Enroll
R

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved